Global health body confesses pharmaceutical industry now experimenting on population like it did during its rollout of the COVID mRNA injections.
The World Health Organization (WHO) admitted that everyone who gets the monkeypox vaccine is part of a clinical trial to gauge whether the shot is effective.
WHO’s chief of infectious hazards preparedness agency Tim Nguyen noted that the monkeypox vaccine’s efficacy isn’t known because it’s never been used on a large scale.
“I would like to underline one thing that is very important to WHO. We do have uncertainty around the effectiveness of these vaccines because they haven’t been used in this context and in this scale before,” Nguyen said Saturday.
Nguyen added that “when these vaccines are being delivered, that they are delivered in the context of clinical trial studies and prospectively collecting this data to increase our understanding of the effectiveness of these vaccines.”
New York City announced it had purchased thousands of doses of JYNNEOS vaccines last week, one of the two FDA-licensed vaccines. The other is called ACAM2000, also known as Imvamune or Imvanex.
“The NY Health Department announced plans for its next allocation of the JYNNEOS vaccine,” the New York City Health Department said in a statement on July 21. “Approximately 26,000 additional doses were delivered to New York City as part of Phase 2b from the federal government and state, and will be distributed via clinics, mass vaccination sites and community-based referrals. Individuals will be able to book appointments for July 24 through August 13.”
WHO’s Director-General, Tedros Adhanom Ghebreyesus overrruled the organization’s advisory committee’s recommendation and declared monkeypox a global health emergency on Saturday.
It appears large-scale experimentation on the public has become the norm following the rollout of the experimental COVID mRNA injections, which fast-tracked clinical trials by a decade via the Emergency Use Authorization that brought the shots to market within a year of formulation.